top of page

Young Ninja Group (ages 3-5)

Public·14 membres

Series 122021 [WORK]



IKØN is the musical incarnation of Nicolas Bestea from Lyon, France. Quickly learning the tricks of the trade to produce his own brand of masterfully crafted psytrance, using a unique blend of progressive leads, sprinkled with a touch of full-on, all carried by deep and powerful bass lines, he swiftly rose within the scene. In 2019, he was added to the already stellar roster of TechSafari Records with incredible releases lining up and with more to come. IKØN is inviting you on a trip; dare to go along, now with this fresh mix in celebration of his No.1 spot remix of the legendary Liquid Ace track 'Let Go'.:: Tracklist ::1/ Liquid Ace - Let Go (IKØN Remix) [Iboga Records]2/ Sonic Species & Vertical Mode - Enigma [HOMmega]3/ Symbolic - Transcendence [TechSafari Records]4/ IKØN - Creating Sun [TechSafari Records]5/ Vertical Mode & Oforia - Billy Boy [HOMmega]6/ IKØN - Higher Dimension [TechSafari Records]7/ Faders - Flying Objects (IKØN Remix) [TechSafari Records]8/ IKØN - Moonbow [TechSafari Records]9/ IKØN - Jupiter [TechSafari Records]:: More info :: ://radiozora.fm/iboga-records-series/ep-39-ikon/




Series 122021


Download: https://www.google.com/url?q=https%3A%2F%2Ftweeat.com%2F2udJwq&sa=D&sntz=1&usg=AOvVaw3NK-FWKoV-XxhMGRJRx7mB



Vaccine booster dose policy decisions should be based on evidence of individual and public health benefit and obligations to secure global equity in vaccine access as a means to minimize health impacts and transmission, and thereby reduce the risk of\r\n variants and prolongation of the pandemic. While vaccine supply is growing, it is not evenly distributed. Lower income countries have had far less access, and face unpredictable and irregular supply. Within countries, equity considerations support\r\n improving coverage of the primary vaccination series in high risk populations as the top priority use of vaccine doses (3).


For some inactivated vaccines (CoronaVac and COVID-19 vaccine BIBP), WHO has already issued the recommendation for the administration of an additional dose to those aged 60 years or older as part of the primary series to make initial immunity\r\n more robust (7, 8).


In several jurisdictions, booster vaccination has been authorized by regulatory authorities and added to the product labels of BNT162b2, mRNA 1273 and Ad26.COV2.S. In addition, for ChAdOx1-S [recombinant] and CoronaVac, COVID-19 vaccine BIBP, BBV152\r\n and NVX-CoV2373 vaccines, clinical trial data of booster doses are available. All studies to date show a strong anamnestic immunological response achieving or improving upon the peak antibody levels following the primary immunization series, but with\r\n insufficient data and too little follow-up to assess the kinetics and duration of the response. Both homologous and heterologous booster regimens are immunologically effective(9).


Safety and reactogenicity studies are based on small-scale clinical trials and post-licensure data with limited follow-up. Overall, they show a similar safety profile to that observed after the second dose in the primary series. Regulatory authorities\r\n and advisory bodies have thus assessed a favourable benefit risk ratio of booster vaccination at an individual level.


At least 126 countries worldwide have already issued recommendations on booster or additional vaccination and more than 120 have started programmatic implementation. The majority of these countries are classified as high-income, or upper middle-income.\r\n No low-income country has yet introduced a booster vaccination programme. The most commonly prioritized target populations for booster doses are older adults, health workers and immunocompromised individuals (in immunocompromised individuals the booster\r\n dose is considered as an additional primary series vaccination dose by WHO). The degree of primary vaccination coverage in the eligible adult population varies. In several of these countries which are administering booster doses the coverage\r\n rates for complete primary vaccination are below 30%.


The focus of COVID-19 immunization efforts must remain on decreasing death and severe disease, and the protection of the health care system. Public health and social measures continue to be an essential component of the COVID-19 prevention strategy, especially\r\n in light of the Omicron variant. In the context of ongoing global vaccine supply constraints and inequities, broad-based administration of booster doses risks exacerbating vaccine access by driving up demand in countries with substantial\r\n vaccine coverage and diverting supply while priority populations in some countries, or in subnational settings, have not yet received a primary vaccination series.


Introducing booster doses should be firmly evidence-driven and targeted to the population groups at highest risk of serious disease and those necessary to protect the health system. To date, the evidence indicates a minimal to modest reduction\r\n of vaccine protection against severe disease over the 6 months after the primary series. Waning of effectiveness against all clinical disease and infection is more pronounced. Duration of protection against the Omicron variant may be altered and is\r\n under active investigation. Evidence on waning vaccine effectiveness, in particular a decline in protection against severe disease in high-risk populations, calls for the development of vaccination strategies optimized for prevention of severe\r\n disease, including the targeted use of booster vaccination.


Vaccine booster dose policy decisions should be based on evidence of individual and public health benefit and obligations to secure global equity in vaccine access as a means to minimize health impacts and transmission, and thereby reduce the risk ofvariants and prolongation of the pandemic. While vaccine supply is growing, it is not evenly distributed. Lower income countries have had far less access, and face unpredictable and irregular supply. Within countries, equity considerations supportimproving coverage of the primary vaccination series in high risk populations as the top priority use of vaccine doses (3).


For some inactivated vaccines (CoronaVac and COVID-19 vaccine BIBP), WHO has already issued the recommendation for the administration of an additional dose to those aged 60 years or older as part of the primary series to make initial immunitymore robust (7, 8).


In several jurisdictions, booster vaccination has been authorized by regulatory authorities and added to the product labels of BNT162b2, mRNA 1273 and Ad26.COV2.S. In addition, for ChAdOx1-S [recombinant] and CoronaVac, COVID-19 vaccine BIBP, BBV152and NVX-CoV2373 vaccines, clinical trial data of booster doses are available. All studies to date show a strong anamnestic immunological response achieving or improving upon the peak antibody levels following the primary immunization series, but withinsufficient data and too little follow-up to assess the kinetics and duration of the response. Both homologous and heterologous booster regimens are immunologically effective(9).


Safety and reactogenicity studies are based on small-scale clinical trials and post-licensure data with limited follow-up. Overall, they show a similar safety profile to that observed after the second dose in the primary series. Regulatory authoritiesand advisory bodies have thus assessed a favourable benefit risk ratio of booster vaccination at an individual level.


At least 126 countries worldwide have already issued recommendations on booster or additional vaccination and more than 120 have started programmatic implementation. The majority of these countries are classified as high-income, or upper middle-income.No low-income country has yet introduced a booster vaccination programme. The most commonly prioritized target populations for booster doses are older adults, health workers and immunocompromised individuals (in immunocompromised individuals the boosterdose is considered as an additional primary series vaccination dose by WHO). The degree of primary vaccination coverage in the eligible adult population varies. In several of these countries which are administering booster doses the coveragerates for complete primary vaccination are below 30%.


The focus of COVID-19 immunization efforts must remain on decreasing death and severe disease, and the protection of the health care system. Public health and social measures continue to be an essential component of the COVID-19 prevention strategy, especiallyin light of the Omicron variant. In the context of ongoing global vaccine supply constraints and inequities, broad-based administration of booster doses risks exacerbating vaccine access by driving up demand in countries with substantialvaccine coverage and diverting supply while priority populations in some countries, or in subnational settings, have not yet received a primary vaccination series.


Introducing booster doses should be firmly evidence-driven and targeted to the population groups at highest risk of serious disease and those necessary to protect the health system. To date, the evidence indicates a minimal to modest reductionof vaccine protection against severe disease over the 6 months after the primary series. Waning of effectiveness against all clinical disease and infection is more pronounced. Duration of protection against the Omicron variant may be altered and isunder active investigation. Evidence on waning vaccine effectiveness, in particular a decline in protection against severe disease in high-risk populations, calls for the development of vaccination strategies optimized for prevention of severedisease, including the targeted use of booster vaccination.


Apple TV+ is available to watch across all your favorite screens. After its launch on November 1, 2019, Apple TV+ became the first all-original streaming service to launch around the world, and has premiered more original hits and received more award recognitions faster than any other streaming service in its debut. To date, Apple Original films, documentaries and series have been honored with 154 wins and 523 awards nominations. 041b061a72


À propos

Welcome to the group! You can connect with other members, ge...
bottom of page